INTRODUCTION
Secondary glaucoma is a common problem in eyes with uveitis, and elevated intraocular pressure (IOP) occurs in 11-46% of eyes with chronic uveitis [1] [2] [3] [4] . Uveitic glaucoma can be difficult to treat because of the relatively young mean patient age, diverse pathogenic factors, prolonged use of topical corticosteroids, and limited tolerance to medical therapies [5] . Accordingly, many patients ultimately require glaucoma surgery to achieve long-term stability [5, 6] . Glaucoma drainage devices are increasingly becoming the preferred procedure in these patients [7] . Administration on the basis of two prospective multicenter randomized pivotal trials to treat eyes with noninfectious posterior uveitis [8] [9] [10] . The Retisert implant produces sustained intraocular corticosteroid delivery for up to 36 months.
However, 70% of the Retisert-implanted eyes showed susceptibility to steroid-induced increased IOP and 33.8% required surgery as reported recently [11] . In another study, the Retisert-implanted eyes had about a fourfold risk of developing IOP elevation of C10 mmHg and incident glaucomatous optic neuropathy compared with those assigned to systemic immunosuppressive therapy for uveitis [12] . Glaucoma drainage devices have been fairly effective in IOP control in eyes with uveitic glaucoma [5] . However, in eyes with uveitic glaucoma requiring treatment with simultaneous Retisert implant and glaucoma drainage devices, the long-term IOP control may be limited due to chronic steroid delivery. 
RESULTS

Preoperative Characteristics
A total of 60 eyes of 60 patients were included in the study. Simultaneous combined Retisert implantation and Ahmed valve placement was performed on 22 uveitic eyes. Ahmed valve alone was performed on 16 uveitic eyes and 22 POAG eyes during the study period. Baseline demographics and implant model are presented in Table 1 . Fifty-nine percent of UG Retisert eyes underwent simultaneous cataract extraction, compared to 25% and 14% in the UG non-Retisert and POAG groups, respectively. The Retisert implant was performed by three vitreoretinal surgeons and the Ahmed implants were performed by four glaucoma surgeons. Of note, there was a significant difference in mean ages in the three groups (P\0.001) and all pair-wise comparisons of age between groups were also significantly different (P\0.006). Of the eyes in the UG Retisert group, 11 were on no systemic immunotherapy. Of the remaining 11 eyes that were on systemic immunosuppressive therapy, 7 stopped such therapy following the Retisert implant and 4 were continued on such therapy for systemic reasons. Such therapy included medications such as methotrexate, oral prednisone, hydroxychloroquine, etanercept, and mycophenolate mofetil. Only one of the eyes of the UG non-Retisert group was being treated with oral immunosuppressive therapy, which was continued postoperatively. All the eyes in both the UG Retisert and UG non-Retisert groups were on varying doses of topical prednisolone prior to surgery and were continued on a slow tapering schedule till both the uveitic valve and POAG valve groups (-0.63 and -0.76, respectively; P = 0.005 and P = 0.017, respectively).
Surgical Success
By Kaplan-Meier survival analysis, there was a significant difference in the duration of surgical success among the UG Retisert compared to both the UG non-Retisert and POAG groups (P = 0.034). The mean surgical success duration was greater in the UG Retisert group (629 ± 53 days) compared to the UG non-Retisert (361 ± 37 days) and the POAG valve (472 ± 65 days) groups. The cumulative probability of success at 1 year was 84%, 63%, and 61% for the UG Retisert, UG non-Retisert, and POAG groups, respectively. The cumulative probability of success at 2 years was 67%, 54%, and 27% in the UG Retisert, UG non-Retisert, and POAG groups, respectively (Fig. 1) 
Postoperative Intraocular Pressure
At 24 months postoperatively, the average IOP was 11.7, 12.1, and 15.0 in the UG Retisert, UG non-Retisert, and POAG groups, respectively.
There was a trend towards significance when comparing the UG Retisert and POAG groups (P = 0.076) and achieving significance between the UG non-Retisert and POAG groups (P = 0.020). The difference in postoperative IOP between the two uveitic groups was not significant. In all three groups, the mean IOPs at all postoperative visits were significantly reduced compared to the preoperative IOP (P\0.01 at all time points). The difference in IOP change between the two uveitic groups was not significant (Fig. 2) . There was no significant difference in IOP or change in IOP when comparing uveitis anatomical location or etiology (P = 0.161-0.923). There were no significant differences in the number of medications used in the UG non-Retisert and UG Retisert groups (P = 0.542 and 0.626 at 12 and 24 months; Fig. 3 ).
Visual Acuity
There were no significant changes in postoperative visual acuities in the UG non-Retisert and POAG groups at the as assessed by Kaplan-Meier analysis [5, 22, 23] . The probability of success in our study was 84% at 1 year and 63% at 2 years in the UG Retisert and 63% at 1 year and 54% at 2 years in the UG There are some possible explanations for the finding that uveitic eyes had lower IOP and fewer medications following glaucoma tube implant than those with POAG. Endogenous prostaglandin release plays a complex and poorly understood role in both uveitis and IOP [30] , and may facilitate some of the success. It is also possible that uveitic eyes have long-term postoperative reduced aqueous production, although no known confirmatory literature exists.
The 
